Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Principal Accounting Officer | February 02, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2036-02-01 | Direct | 57,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 57,000 · Balance 57,000 F1: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 4, 2026 21:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 57,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001193125-26-037575 · ownership.xml · derivative · entry 1 Tourangeau Greg · CIK 0001916566 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| May 08, 2025 Filed May 9, 2025 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 498 | $5.06 | $2,519.88 |
DisclosureSEC source: 0000950170-25-068038 · ownership.xml · nonDerivative · entry 1 Tourangeau Greg · CIK 0001916566 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,062 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 2,989 shares acquired under the Issuer's employee stock purchase plan on May 14, 2024. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 76,120 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-25-009815 · ownership.xml · derivative · entry 1 Tourangeau Greg · CIK 0001916566 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,120 Underlying: Common Stock · 76,120 shares Expires 2035-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2025 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2025, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 236 | $7.76 | $1,831.36 |
DisclosureSEC source: 0000950170-24-056947 · ownership.xml · nonDerivative · entry 1 Tourangeau Greg · CIK 0001916566 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,571 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 08, 2024 Filed Mar 8, 2024 23:05 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 4,884 | $11.72 | $57,218.50 |
DisclosureSEC source: 0000950170-24-028827 · ownership.xml · nonDerivative · entry 1 Tourangeau Greg · CIK 0001916566 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,807 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.71 to $11.74, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes 699 shares acquired under the Issuer's employee stock purchase plan on May 13, 2022. Read SEC document |
| January 26, 2024 Filed Jan 31, 2024 02:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0000950170-24-009096 · ownership.xml · derivative · entry 2 Tourangeau Greg · CIK 0001916566 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-25 F2 · derivative.exercise_date: This option was granted on January 26, 2024 and is scheduled to vest in equal yearly installments over two years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| January 26, 2024 Filed Jan 31, 2024 02:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 83,820 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0000950170-24-009096 · ownership.xml · derivative · entry 1 Tourangeau Greg · CIK 0001916566 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,820 Underlying: Common Stock · 83,820 shares Expires 2034-01-25 F1 · derivative.exercise_date: This option was granted on January 26, 2024 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2024, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:12 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 210 | $3.31 | $695.10 |
DisclosureSEC source: 0000950170-23-021245 · ownership.xml · nonDerivative · entry 1 Tourangeau Greg · CIK 0001916566 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,992 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 16,100 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0000899243-23-004744 · doc4.xml · derivative · entry 1 Tourangeau Greg · CIK 0001916566 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,100 Underlying: Common Stock · 16,100 shares Expires 2033-02-08 F1 · derivative.exercise_date: This option was granted on February 9, 2023 and is is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 16,540 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0000899243-22-026322 · doc4.xml · derivative · entry 1 Tourangeau Greg · CIK 0001916566 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,540 Underlying: Common Stock · 16,540 shares Expires 2032-07-14 F1 · derivative.exercise_date: This option was granted on July 15, 2022 and is is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of July 1, 2022, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-22-017416 · doc4.xml · derivative · entry 2 Tourangeau Greg · CIK 0001916566 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-05-05 F2 · derivative.exercise_date: This option was granted on May 6, 2022 and is subject to time-based vesting, with (i) 25% of the options vesting on May 6, 2023, (ii) 25% of the options vesting on May 6, 2024, and (iii) 50% of the options vesting on May 6, 2025, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017416 · doc4.xml · nonDerivative · entry 1 Tourangeau Greg · CIK 0001916566 · Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,202 F1 · price: These shares represent restricted stock unit (RSU) awards granted on May 6, 2022, with each RSU representing a right to receive one share of common stock. The RSU is subject to time-based vesting with (i) 25% of the shares vesting on May 6, 2023, (ii) 25% of the shares vesting on May 6, 2024, and (iii) 50% of the shares vesting on May 6, 2025, subject to the reporting person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.